Centre bans over 350 drug combinations

Nagpur: The Union government, through Drugs Controller General of India (DCGI), informed the Nagpur bench of Bombay High Court on Thursday that it had banned over 350 fixed drugs combinations (FDC), which the experts believed have irreversible and adverse effects on vital human organs.

The reply came while hearing a suo motu PIL (No 18/2010) on a media report over sale of spurious drugs in Nagpur district. Anand Parchure was appointed as amicus curiae.

Earlier, the India Medical Association (IMA) filed an affidavit stating that it was creating awareness among doctors and patients regarding use of banned drugs.

Parchure had made a prayer in this regard in the PIL along with banning of drugs.

A division bench comprising justice Bhushan Gavai and justice Vinay Deshpande then disposed of the case stating that purpose of PIL was served.

The IMA had submitted a list of about 87 drug combinations terming them as "irrational". It was prepared by a court appointed expert panel headed by the Department of Pharmacology, Government Medical College & Hospital in the city, in 2010. IMA pointed out that majority of these combinations were prohibited in many countries.

Parchure then pointed out that DCGI had met in this regard in 2011 after the panel submitted its report to the court. Then it again met after four years in February last year, but failed to take any concrete action against these 87 drugs.

The judges tersely observed that the DCGI's work was going on at a snail's pace and warned its director that he would have to personally remain present if decision was not taken within stipulated period.

This Website Uses Cookies

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you've provided to them or that they've collected from your use of their services. Give your consent to our cookies for: